Edward R Scheffer Cliff
Overview
Explore the profile of Edward R Scheffer Cliff including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
118
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Elshiekh C, Ruda R, Cliff E, Gany F, Budhu J
Neurooncol Pract
. 2025 Jan;
12(Suppl 1):i49-i58.
PMID: 39776525
The isocitrate dehydrogenase (IDH) inhibitor, vorasidenib, may offer a promising new treatment option for patients with IDH-mutant gliomas. However, the indefinite nature of this targeted therapy raises significant financial concerns....
2.
Hillis J, Cliff E, Vokinger K
JAMA Neurol
. 2024 Nov;
82(2):117-118.
PMID: 39556390
No abstract available.
3.
Erfani P, Okediji R, Mulema V, Cliff E, Asante-Shongwe K, Bychkovksy B, et al.
JAMA Oncol
. 2024 Nov;
11(1):55-59.
PMID: 39541207
Importance: Limited availability and affordability of cancer drugs contribute to staggering disparities in cancer survival between high-income and low- and middle-income countries (LMICs). As infrastructure for cancer care rapidly develops,...
4.
Daval C, Kesselheim A, Cliff E
N Engl J Med
. 2024 Oct;
391(14):1273-1275.
PMID: 39373384
No abstract available.
5.
Zhukovsky S, Cliff E, Mohyuddin G
Lancet Haematol
. 2024 Oct;
11(10):e715-e717.
PMID: 39362738
No abstract available.
6.
Zhukovsky S, White J, Chakraborty R, Costa L, Van Oekelen O, Sborov D, et al.
Leuk Lymphoma
. 2024 Sep;
65(14):2163-2172.
PMID: 39314111
Patients with certain subsets of multiple myeloma continue to have poor outcomes and are in need of novel treatment approaches. Strict eligibility criteria for randomized controlled trials (RCTs) limit access...
7.
Tix T, Alhomoud M, Shouval R, Cliff E, Perales M, Cordas Dos Santos D, et al.
Clin Cancer Res
. 2024 Sep;
30(20):4690-4700.
PMID: 39256908
Purpose: Chimeric antigen receptor (CAR) T-cell therapy is a potent immunotherapy for hematologic malignancies, but patients can develop long-term adverse events, including second primary malignancies (SPM) that impact morbidity and...
8.
Kakkilaya A, Trando A, Cliff E, Mian H, Al Hadidi S, Aziz M, et al.
Oncologist
. 2024 Sep;
30(2).
PMID: 39236068
Background: Smoldering multiple myeloma (SMM), an asymptomatic precursor of multiple myeloma (MM), carries a variable risk of progression to MM. There is little consensus on the efficacy or optimal timing...
9.
Chakraborty R, Cheruvalath H, Patwari A, Szabo A, Schinke C, Dhakal B, et al.
Blood Cancer J
. 2024 Aug;
14(1):137.
PMID: 39134535
No abstract available.
10.